Table 3. Significant associations (P<0.05) of reported-T2D loci with quantitative glycemic traits in controls of the DMS case-control sample.
Fasting glucose | OGTT 2-h glucose | Fasting insulinb | ||||||||||||
(mmol) | (mmol/l) | (pmol/l) | HOMA_IRb | HOMA_Bb | Insulinogenic indexb | |||||||||
SNP | Nearby gene | Effect allelea | β (SE) | P-value | β (SE) | P-value | β (SE) | P-value | β (SE) | P-value | β (SE) | P-value | β (SE) | P-value |
rs780094 | GCKR | G | 0.02 (0.01) | 0.07 | 0.03 (0.02) | 0.17 | 0.01 (0.01) | 0.43 | 0.01 (0.01) | 0.21 | −0.01 (0.01) | 0.52 | 0.05 (0.02) | 0.047 |
rs243021 | BCL11A c | T | 0.02 (0.01) | 0.055 | −0.03 (0.02) | 0.24 | 0.02 (0.01) | 0.08 | 0.02 (0.01) | 0.03 | 0 (0.01) | 0.91 | 0.02 (0.03) | 0.41 |
rs4607103 | ADAMTS9 c | C | 0.01 (0.01) | 0.25 | 0.02 (0.02) | 0.45 | 0 (0.01) | 0.67 | 0.01 (0.01) | 0.56 | 0 (0.01) | 0.95 | −0.07 (0.02) | 5.33×10−3 |
rs7756992 | CDKAL1 | G | 0.02 (0.01) | 0.09 | 0.04 (0.02) | 0.055 | −0.01 (0.01) | 0.21 | −0.01 (0.01) | 0.37 | −0.02 (0.01) | 0.12 | −0.07 (0.02) | 6.21×10−3 |
rs896854 | TP53INP1 | A | 0.01 (0.01) | 0.20 | −0.01 (0.02) | 0.65 | −0.03 (0.01) | 0.01 | −0.02 (0.01) | 0.03 | −0.03 (0.01) | 0.04 | −0.03 (0.03) | 0.32 |
rs10811661 | CDKN2A/B c | T | 0.01 (0.01) | 0.49 | 0.06 (0.02) | 9.11×10−3 | 0 (0.01) | 0.96 | 0 (0.01) | 0.78 | −0.01 (0.01) | 0.53 | −0.05 (0.02) | 0.03 |
rs13292136 | CHCHD9 c | C | −0.02 (0.02) | 0.42 | −0.08 (0.04) | 0.03 | −0.02 (0.02) | 0.32 | −0.02 (0.02) | 0.28 | −0.01 (0.02) | 0.78 | −0.04 (0.04) | 0.33 |
rs12779790 | CDC123 c | G | 0.01 (0.01) | 0.60 | 0.02 (0.03) | 0.42 | 0.03 (0.01) | 8.58×10−3 | 0.04 (0.01) | 9.39×10−3 | 0.02 (0.02) | 0.18 | 0 (0.03) | 0.99 |
rs1111875 | HHEX c | G | −0.02 (0.01) | 0.12 | −0.01 (0.03) | 0.79 | −0.01 (0.01) | 0.29 | −0.02 (0.01) | 0.17 | 0.01 (0.02) | 0.71 | −0.09 (0.03) | 6.73×10−4 |
rs7903146 | TCF7L2 | T | 0.03 (0.03) | 0.34 | 0.17 (0.06) | 4.90×10−3 | 0.03 (0.03) | 0.26 | 0.03 (0.03) | 0.24 | 0.02 (0.04) | 0.48 | −0.01 (0.06) | 0.87 |
rs10830963 | MTNR1B | G | 0.03 (0.01) | 5.50×10−3 | 0 (0.02) | 0.86 | 0 (0.01) | 0.83 | 0.01 (0.01) | 0.43 | −0.02 (0.01) | 0.16 | −0.02 (0.02) | 0.43 |
rs11634397 | ZFAND6 c | G | −0.03 (0.02) | 0.12 | −0.05 (0.04) | 0.21 | 0 (0.02) | 0.78 | 0 (0.02) | 0.97 | 0.03 (0.02) | 0.15 | −0.11 (0.04) | 4.67×10−3 |
rs9939609 | FTO | A | −0.01 (0.02) | 0.75 | 0 (0.04) | 0.90 | −0.04 (0.02) | 0.02 | −0.04 (0.02) | 0.02 | −0.02 (0.02) | 0.33 | 0.01 (0.04) | 0.73 |
P-values <0.05 are shown in bold.
Previously reported risk alleles.
Log-transformed values were used in general linear regression models.
The nearest gene is provided if a SNP is intergenic.
HOMA-B, homoeostasis model assessment of beta-cell function; HOMA-IR, homoeostasis model assessment of insulin resistance; OGTT, oral glucose tolerance test; SE, standard error; SNP, single nucleotide polymorphism.